Horama Company
Horama develops gene therapies for rare inherited ocular diseases.
Total Funding:
â¬27.1M
Investor Type:
Company
Technology:
Neurological Disorders
Investment Stage:
N/A
Last Funding Type:
Series B
Estimated Revenue:
$1M to $10M
Founded Date:
2014
Industry:
Gene Therapy
Employee Number:
11-50
Funding Status:
Early Stage Venture
Number Of Exists:
Series B
Headquarters:
Paris, Ile-de-France, France
Investors Number:
9